About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.
CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company with headquarters in Melbourne, Australia. For more information visit http://www.cslbehring.com . CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.
Contact: Sheila A. Burke, Director, Communications & Public RelationsWorldwide Commercial OperationsCSL Behring610-878-4209 (o)484-919-2618 (c) Sheila.Burke@cslbehring.com
SOURCE CSL Behring